Departments of Biochemistry and Pathology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
Science. 2013 Dec 13;342(6164):1385-9. doi: 10.1126/science.1243106. Epub 2013 Nov 21.
Oxamniquine resistance evolved in the human blood fluke (Schistosoma mansoni) in Brazil in the 1970s. We crossed parental parasites differing ~500-fold in drug response, determined drug sensitivity and marker segregation in clonally derived second-generation progeny, and identified a single quantitative trait locus (logarithm of odds = 31) on chromosome 6. A sulfotransferase was identified as the causative gene by using RNA interference knockdown and biochemical complementation assays, and we subsequently demonstrated independent origins of loss-of-function mutations in field-derived and laboratory-selected resistant parasites. These results demonstrate the utility of linkage mapping in a human helminth parasite, while crystallographic analyses of protein-drug interactions illuminate the mode of drug action and provide a framework for rational design of oxamniquine derivatives that kill both S. mansoni and S. haematobium, the two species responsible for >99% of schistosomiasis cases worldwide.
奥沙尼喹耐药性在 20 世纪 70 年代在巴西的人体血吸虫(曼氏血吸虫)中产生。我们杂交了对药物反应差异约 500 倍的亲代寄生虫,在克隆衍生的第二代后代中确定了药物敏感性和标记分离,并在第 6 号染色体上确定了一个单一的数量性状基因座(优势对数= 31)。通过使用 RNA 干扰敲低和生化互补测定,鉴定出磺基转移酶是致病基因,随后我们证明了在现场衍生和实验室选择的耐药寄生虫中功能丧失突变的独立起源。这些结果证明了连锁图谱在人类寄生虫中的实用性,而蛋白质-药物相互作用的晶体学分析阐明了药物作用模式,并为设计既能杀死引起全球 99%以上血吸虫病的曼氏血吸虫和埃及血吸虫的奥沙尼喹衍生物提供了框架。